Westlaw Journals weekly round-up

March 19, 2014

Westlaw Journals Weekly RoundupLast week, I was away, but I’m back now with some goodies. Highlights from the past week’s litigation headlines over at the Westlaw Journals blog include a suit over testosterone drug AndroGel, federal guidance for marijuana businesses and Delaware high court ruling on admissibility of social media evidence:

Abbott’s AndroGel caused life-threatening blood clots, suit says: Abbott Labs’ blockbuster testosterone drug AndroGel caused a retired policeman to develop blood clots that blocked his pulmonary arteries, according to a Chicago federal court lawsuit. In a suit filed Feb. 10 in the U.S. District Court for the Northern District of Illinois, Roger Gibby says that after using the medication, he was hospitalized last September with multiple blood clots in his lungs and legs. (Pharmaceutical)

Federal guidance helps banks serve legal marijuana businesses: The federal government has issued new guidance on the customer due diligence and reporting requirements for financial institutions providing services to legal marijuana businesses. Issued by the Treasury Department’s Financial Crimes Enforcement Network in coordination with the Department of Justice on Feb. 14, the guidance will help banks, credit unions and money services firms comply with the Bank Secrecy Act when doing business with marijuana-related companies. (Bank & Lender Liability)

Del. high court says jury decides authenticity of social media evidence: Social media posts are like any other evidence under the Delaware rules, the state high court has announced in a criminal case involving allegations of assault. Therefore, the New Castle County Superior Court did not err when it admitted Facebook posts along with circumstantial evidence that they came from defendant Tiffany Parker’s account, and allowed a jury to decide their authenticity, the Delaware Supreme Court decided Feb. 5. (Computer & Internet)